Q2 2020 Aerie Pharmaceuticals Inc Earnings Call
שיחת ועידה Aerie Pharmaceuticals Inc
Aerie Pharmaceuticals Inc Conference call or earnings call will be held on 06/08/2020 via an 800 number (toll-free). During the earnings conference call's session Aerie Pharmaceuticals Inc will provide updated information and financial status.
Conference call is also referred to as: teleconference call or audio conference bridge. Conferencing service is provided in house or as cloud based teleconference service.
In order to join the audio conferencing dial conference bridge and key in the PIN code, Contact Aerie Pharmaceuticals Inc for this information
Schedule a teleconference with QCONF and get 5 free calls with our conference service.
We are a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye. Our strategy is to advance our product candidates, including Rhopressa(TM) (netarsudil ophthalmic solution) 0.02%, and Roclatan(TM) (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, to regulatory approval and commercialize these products ourselves in North American markets. We plan to build a commercial team of approximately 100 sales representatives to target approximately 10,000 high prescribing eye-care professionals throughout North America. We are also directing our own clinical trials to gain regulatory approval in Europe, and are preparing to either use a contract research organization, or otherwise partner, to conduct the necessary trials to gain approval in Japan.קרא עוד שיחת ועידה